IL17A and psoriasis: As the first biologic targeting IL-17 approved for the management of psoriasis, secukinumab has been proven to provide safe, rapid, and sustained improvements in patients with plaque psoriasis, psoriatic arthritis (PsA), and ankylosing spondylitis.